Fundraising Fox

Prolocor

Philadelphia, US · Founded 2020 · Delaware corporation · 1 known investors

Prolocor is developing diagnostic tests related to atherosclerotic cardiovascular disease and thrombotic risk, including platelet FcγRIIa-based assessment of risk in cancer patients. Its work is oriented toward clinical and medical diagnostics in the United States.

Founders & leadership

Prolocor was founded in 2020 by Peter M. DiBattiste, David Schneider, and David J. Schneider.

PM
Peter M. DiBattisteinCo-founder & CEO
DS
David SchneiderCo-founder
DJ
David J. SchneiderinCo-founder & CSO

Investors · 1

Funding

SEC filings, press & company announcements

$1.6M disclosed across 1 of 2 rounds · 2021–2024

$1.6MraisedJan 2022 · 11 investors · Biotechnology
Officers, directors & promoters on the filing
  • Peter M. DiBattisteExecutive Officer, Director
  • David SchneiderExecutive Officer, Director
Offering amount
$3M
Amount sold
$1.6M
First sale
Jul 2021
Incorporated
Corporation, Delaware, 2020
Federal exemptions
04.3
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Companies competing with Prolocor for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

What does Prolocor do?
Prolocor is developing diagnostic tests related to atherosclerotic cardiovascular disease and thrombotic risk, including platelet FcγRIIa-based assessment of risk in cancer patients. Its work is oriented toward clinical and medical diagnostics in the United States.
Who founded Prolocor?
Prolocor was founded by Peter M. DiBattiste, David Schneider, David J. Schneider in 2020.
Who are Prolocor's investors?
Prolocor's investors include Green Park & Golf Ventures.
How much funding has Prolocor raised?
Prolocor has disclosed $1.6M raised across 1 of its 2 known rounds.
Where is Prolocor headquartered?
Prolocor is headquartered in Philadelphia, US.